Grünenthal to acquire Bayer's cancer drug Stivarga for up to €375m
- Location
- Aachen (buyer) / Leverkusen (seller) · 🇩🇪 Germany
- Sector
- Pharma
- Organisations
- Grünenthal Group ↔ Bayer AG — Krebsmedikament Stivarga® (Regorafenib)
- Transaction
- Acquisition of worldwide product rights
- Volume
- up to €375 million
- Status
- announced
On 21 September 2026 Aachen-based pharmaceutical company Grünenthal announced an agreement with Bayer AG to acquire the cancer medicine Stivarga® (regorafenib) for up to €375 million. The oral medicine is approved to treat certain advanced cancers — including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma — and is available in more than 90 markets. The acquisition is subject to customary closing conditions; Grünenthal has invested around €2.6 billion in M&A transactions since 2017. (Source: Grünenthal Group via Presseportal/ots, 21 Sep 2026)
Source: presseportal.de ↗ · Archived copy ↗
Evidence: one source · archived copy saved · How well sourced is Eurotrack?
More from: 🇩🇪 Germany